Results 131 to 140 of about 9,676 (179)

HCV NS3/4A protease relocalizes CCTα to viral replication sites, enhancing phosphatidylcholine synthesis and viral replication. [PDF]

Proc Natl Acad Sci U S A
Sarwar S, Randall G.
europepmc   +1 more source

Protein tyrosine kinase Src suppresses hepatitis C virus particle release through regulation of Ndrg1. [PDF]

J Biol Chem
Fu L, Takeuchi K, Chihara K, Feng W, Sada K.   +4 more
europepmc   +1 more source

Mechanisms of Viral Oncogenesis: DNA and RNA Viruses in Human Cancer. [PDF]

J Inflamm Res
Yao N, Huang B.
europepmc   +1 more source

The architecture of membrane structures involved in hepatitis C virus genome replication revealed in close-to-native conditions by cryo-electron tomography

Sykora UM, O’ Sullivan TJ, Halfon Y, Fontana J, Harris M.   +4 more
europepmc   +1 more source

Characterizations of HCV NS5A replication complex inhibitors

Virology, 2013
The hepatitis C virus NS5A protein is an established and clinically validated target for antiviral intervention by small molecules. Characterizations are presented of compounds identified as potent inhibitors of HCV replication to provide insight into structural elements that interact with the NS5A protein.
Donald R O'Boyle, Jin-Hua Sun, Peter T Nower   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

NS5A Inhibitors

Current Hepatitis Reports, 2012
As a result of rapid advance medicinal chemistry, the time frame 2011–2012 has been an exciting one that has witnessed the release of the first direct acting antiviral agents (DAA). Multiple enzymatic and protein regions of the virus can serve as targets for these new drugs. One of the newest and most promising of these targets is the NS5A protein. The
Christopher O’Brien, Nicholas Agresti
openaire   +1 more source

Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A Inhibitor

Antiviral Therapy, 2012
Background Daclatasvir (BMS-790052) is an investigational molecule that inhibits the HCV NS5A protein and shows potent antiviral activity apparently across all HCV genotypes. Selection of drug resistance mutations has been reported only for HCV genotype 1, and no information exists for other HCV variants and/or ...
Plaza, Zulema, Soriano, Vincent, Vispo, Eugenia, del Mar Gonzalez, Maria, Barreiro, Pablo, Seclén, Eduardo, Poveda, Eva   +6 more
openaire   +2 more sources

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

Biochemical and Biophysical Research Communications, 2018
Patients with chronic hepatitis C virus (HCV) infection who have failed to respond to direct-acting antiviral (DAA) treatment often acquire drug resistance-associated variants (RAVs). The NS5A-P32 deletion (P32del) RAV confers potent resistance to NS5A inhibitors; therefore, patients who acquire this deletion are likely to fail to respond to DAA re ...
Takuro Uchida, Michio Imamura, Mitsutaka Osawa   +2 more
exaly   +3 more sources